Conventionally, adoptive immunotherapy using lymphokine-activated killer cells, which are patient-derived high-dose IL-2-stimulated PBMCs, presented the possibility of a new treatment for patients with malignant glioma, including GBM. The gene discussed is IL2; the disease is malignant glioma.